| Immunomodulatory placental-expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty. [15] | Randomized, double blind, and placebo-controlled, phase I/IIa study | 20 | Skeletal muscle injury – hip arthroplasty model | Winkler, (2018) |
| Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. [17] | Randomized, controlled, double-blind clinical trial | 20 | Knee osteoarthritis | Soltani, (2018) |
| Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. [20] | Prospective, non-controlled, phase I clinical trial | 8 | Erectile dysfunction | Levy, (2016) |
| Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. [23] | Prospective, non-controlled, single-center, open-label phase I trial | 4 | Chronic pulmonary sarcoidosis | Baughman, (2015) |
| A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. [24] | Single center, non-randomized, dose escalation phase Ib trial | 8 | Idiopathic pulmonary fibrosis | Chambers, (2014) |
| Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. [28] | Prospective, non-controlled, phase I clinical trial | 10 | Type 2 diabetes | Jiang, (2011) |
| Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. [31] | Multicenter, randomized, double-blind, placebo-controlled, 2-dose ranging, phase Ib study | 16 | Multiple sclerosis | Lublin, (2014) |
| Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (rimecard trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). [34] | Randomized, controlled trial, Phase I/II | 30 | Chronic stable heart failure and reduced ejection fraction | Bartolucci, (2017) |
| Effect of intramyocardial grafting collagen scaffold with mesenchymal stromal cells in patients with chronic ischemic heart disease: a randomized clinical trial.[35] | Randomized, double-blind clinical trial | 50 | Chronic ischemic heart disease | He, (2020) |
| Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. [36] | Randomized, controlled, phase I/II trial | 26 | Knee osteoarthritis | Matas, (2019) |
| Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. [38] | Prospective phase I/II study | 64 | Rheumatoid arthritis | Wang, (2019) |
| Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial. [41] | Randomized controlled clinical trial | 82 | Crohn’s disease | Zhang, (2018) |
| Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. [42] | Open-label, single-arm, single-center phase I/ II trial | 20 | Multiple sclerosis | Riordan, (2018) |
| Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial. [43] | Multicenter randomized controlled trial | 42 | Renal transplantation | Sun, (2018) |
| A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. [44] | Randomized, controlled trial | 27 | Acute liver allograft rejection | Shi, (2017) |
| Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial. [45] | Prospective, non-controlled, phase I clinical trial | 26 | Infertility caused by recurrent intrauterine adhesions | Cao, (2018) |
| Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial. [47] | Single-center, open-label, dose-escalation phase I clinical trial | 15 | Severe sepsis | He, (2018) |
| Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. [48] | Parallel assigned controlled, non-randomized, phase I clinical trial | 18 | COVID-19 | Meng, (2020) |
| Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. [49] | Single-center open-label, individually randomized, standard treatment-controlled trial | 41 | COVID-19 | Shu, (2020) |
